Literature DB >> 9314460

Candidal meningitis in HIV-infected patients: analysis of 14 cases.

J L Casado1, C Quereda, J Oliva, E Navas, A Moreno, V Pintado, J Cobo, I Corral.   

Abstract

Five cases of candidal meningitis in human immunodeficiency virus (HIV)-infected patients have been diagnosed in our hospital. This article describes these cases and reviews another nine previously reported in the literature. Most patients (71%) had at least one well-known predisposing factor for candidiasis. Median CD4 cell count was 135/mm3. Headache and fever, in the absence of focal neurologic signs, were the predominant clinical features. The CSF analysis revealed mild pleocytosis and hypoglycorrachia, indistinguishable from those seen in tuberculous or cryptococcal meningitis. Twelve patients (92%) received amphotericin B for a median of 51 days, in combination with flucytosine in five cases. The overall mortality among treated patients was 31%. Although the risk of relapse of candidal meningitis is unknown, maintenance antifungal therapy was given to seven patients (63%), usually with fluconazole. Candida species must be kept in mind as a cause of chronic meningitis in HIV-infected patients who have a known predisposing factor.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9314460     DOI: 10.1086/513746

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  15 in total

Review 1.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

Review 2.  Synergistic combinations of antifungals and anti-virulence agents to fight against Candida albicans.

Authors:  Jinhui Cui; Biao Ren; Yaojun Tong; Huanqin Dai; Lixin Zhang
Journal:  Virulence       Date:  2015       Impact factor: 5.882

3.  Refractory candidal meningitis in an immunocompromised patient cured by caspofungin.

Authors:  Kung-Hung Liu; Chi-Jung Wu; Chen-Hsi Chou; Hsin-Chun Lee; Nan-Yao Lee; Shao-Tsung Hung; Wen-Chien Ko
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

Review 4.  Antifungal combination therapy: clinical potential.

Authors:  John W Baddley; Peter G Pappas
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Fatal immune reconstitution inflammatory syndrome with human immunodeficiency virus infection and Candida meningitis: case report and review of the literature.

Authors:  Jennifer L Berkeley; Avindra Nath; Carlos A Pardo
Journal:  J Neurovirol       Date:  2008-05       Impact factor: 2.643

6.  Adenosine deaminase activity in cerebrospinal fluid of HIV-infected patients: limited value for diagnosis of tuberculous meningitis.

Authors:  I Corral; C Quereda; E Navas; P Martín-Dávila; M-J Pérez-Elías; J-L Casado; V Pintado; J Cobo; E Pallarés; J Rubí; S Moreno
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-05-13       Impact factor: 3.267

7.  Candida species isolated from cerebrospinal fluid.

Authors:  E Dorko; E Pilipcinec; L Tkáciková
Journal:  Folia Microbiol (Praha)       Date:  2002       Impact factor: 2.099

8.  Self-assembled cationic peptide nanoparticles as an efficient antimicrobial agent.

Authors:  Lihong Liu; Kaijin Xu; Huaying Wang; P K Jeremy Tan; Weimin Fan; Subbu S Venkatraman; Lanjuan Li; Yi-Yan Yang
Journal:  Nat Nanotechnol       Date:  2009-06-28       Impact factor: 39.213

9.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2015-12-16       Impact factor: 9.079

10.  Candida dubliniensis meningitis as delayed sequela of treated C. dubliniensis fungemia.

Authors:  Sebastian J van Hal; Damien Stark; John Harkness; Deborah Marriott
Journal:  Emerg Infect Dis       Date:  2008-02       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.